Forensic DNA analysis often begins with imperfect material. Crime scene samples may be degraded, inhibited or present at very low levels. In these situations, the reliability of quantification and the ability to distinguish true signal from noise become critical. Digital PCR (dPCR) is now being explored in forensics because it directly addresses these challenges.
Unlike quantitative PCR, which relies on standard curves and relative measurements, dPCR partitions a sample into thousands of individual reactions. Each partition is scored as positive or negative for the target sequence. Digital PCR delivers absolute quantification without the need for external standards. This approach improves reproducibility between laboratories, reduces bias introduced by amplification efficiency and increases tolerance to inhibitors commonly found in forensic samples.
For forensic scientists, these advantages translate into practical benefits. Digital PCR enables accurate quantification of nuclear and mitochondrial DNA from highly compromised samples, supports informed triage decisions before downstream analysis and opens new opportunities for applications such as mitochondrial DNA sequencing and body fluid identification using RNA markers.
Recent webinar by Dr. David Ballard and Michael Menear at King’s College London highlights how digital PCR can be applied to address some of the most persistent questions in forensic DNA analysis. Learn more in their Q&A below.
Using dPCR to support forensic decision-making
Q: Would you perform nuclear DNA quantification on the QIAcuity Digital PCR System to triage samples for a nuclear MPS workflow?
A: Yes. Single-copy nuclear DNA assays have been successfully implemented on the QIAcuity platform as a replacement for traditional qPCR quantification. The absence of standards simplifies setup, reduces variability and delivers results that align with expectations from downstream testing. The workflow is fast and straightforward, making it well-suited for routine triage prior to massively parallel sequencing.
Q: How simple are digital PCR assays to set up?
A: Digital PCR assays are set up in much the same way as conventional PCR. QIAGEN provides a probe master mix and once primers and probes are combined, reaction preparation is simple. The QIAcuity software is intuitive, allowing users to save mixes, upload plate layouts via Excel and rapidly configure runs. Depending on the assay and number of samples, run times can be as short as approximately 1.5 hours.
Q: How many body fluid markers can you run together in one assay?
A: Current body fluid identification assays routinely multiplex up to five markers. Expansion to six markers is feasible and under consideration, including the potential addition of rectal mucosa markers. The QIAcuity platform supports higher levels of multiplexing through amplitude-based strategies, theoretically enabling up to eight or even twelve targets, although additional validation is required before adopting such approaches in forensic workflows.
Q: How likely are you to implement these assays in casework?
A: Mitochondrial DNA quantification by digital PCR is ready for implementation following validation and documentation and is expected to be introduced into casework in the near term. Body fluid identification assays based on mRNA show strong promise but require additional testing across donors, sample types and conditions before routine casework adoption.
Understanding partitioning and quantification in digital PCR
Q: How do we know there is only one target per partition? Are targets or probes limiting quantification?
A: The goal in digital PCR is to distribute targets so that most positive partitions contain a single copy. In practice, samples are not perfectly homogenized. The QIAcuity software applies Poisson statistics using the ratio of positive, negative and valid partitions to calculate the average number of targets per partition. At low copy numbers, most positive partitions contain one target. At higher concentrations, multiple occupancy increases and is mathematically corrected. If saturation occurs, samples can be diluted or analyzed using higher-partition plates, such as 26K nanoplates, to extend the dynamic range.
Q: Can digital PCR reliably differentiate highly degraded DNA fragments and what are the detection limits?
A: Detection limits are primarily defined by assay design. Digital PCR assays targeting fragments as short as 64 bp have proven effective for degraded mitochondrial DNA. This length balances sensitivity with primer and probe design constraints. Such targets are suitable for degraded nuclear DNA and many SNP-based applications. Shorter targets may be possible using alternative chemistries, but 64 bp has shown robust performance in forensic contexts.
Q: How can digital PCR assist in validating novel forensic markers such as SNPs or epigenetic signatures?
A: The suitability of digital PCR depends on the application. While it is not ideal for high-density SNP genotyping requiring hundreds or thousands of markers, it can be useful for targeted validation of specific markers. DNA methylation assays are a particularly interesting future application. Digital PCR offers flexibility but is best suited to focused, hypothesis-driven marker analysis rather than large-scale genotyping.
RNA analysis and body fluid identification
Q: Would you recommend DNA/RNA co-extraction or separate RNA extraction?
A: DNA/RNA co-extraction is preferred for streamlined forensic workflows and higher throughput. However, residual DNA can increase background fluorescence in RNA assays. DNase treatment improves clarity. With careful assay design targeting exon–exon junctions, co-extraction performs well and allows both DNA profiling and body fluid identification from a single sample.
Q: What approach was used for cDNA priming, first strand or double-stranded?
A: Two approaches were evaluated. A two-step method generates cDNA using random hexamers prior to digital PCR and offers high sensitivity. A one-step method performs reverse transcription directly on the digital PCR instrument using target-specific primers. While this simplifies workflow and increases specificity, it currently shows slightly reduced sensitivity.
Q: Have you tested body fluid assays on older samples?
A: Testing to date has focused on fresh samples from multiple donors to optimize assay performance. Future work will include aged samples, sensitivity studies and broader validation.
Q: Have you verified that assays do not cross-react with prokaryotic nucleic acids?
A: Yes. All targeted mRNA markers show no cross-reactivity with prokaryotic nucleic acids.
Q: How might low-level markers such as saliva perform in real casework samples?
A: Saliva samples often contain a high proportion of bacterial nucleic acids. Total RNA measurements may overestimate human RNA content. Human-specific digital PCR assays provide a more accurate assessment but may reveal lower copy numbers than expected. Further testing is underway to evaluate performance in real casework scenarios.
Mitochondrial DNA quantification and interpretation
Q: What volume of extract does mitochondrial digital PCR require?
A: Input volumes typically range from 1 to 20 µL, with 2 µL commonly used in practice.
Q: How many samples can be run simultaneously?
A: Plate formats support up to 96 wells. Allowing for controls, up to 94 samples can be analyzed in a single run.
Q: How challenging is multiplex optimization using digital PCR?
A: Optimization challenges are similar to those encountered with qPCR. Most dye channels perform well, though some require careful selection. The QIAcuity platform offers additional dye options, including far-red and long Stokes-shift dyes, to minimize spectral overlap.
Q: What strategies help address spectral cross-talk in multiplex assays?
A: Using dyes with well-separated emission spectra and limiting multiplex complexity reduces cross-talk. Running multiple focused assays rather than a single highly complex multiplex can improve robustness.
Q: What software tools support quality control and reporting?
A: QIAcuity software provides intuitive visualization tools, including 1D and 2D scatter plots, signal maps and automated reports. Data can be exported as CSV files for further analysis. Confidence intervals are provided for copy number estimates, supporting transparent forensic reporting.
Broader forensic applications
Q: Can digital PCR identify microbes at a crime scene?
A: Yes. Species-, genus- or family-specific primers enable microbial detection for forensic or environmental applications.
Q: Can digital PCR distinguish mixed DNA profiles more effectively than current methods?
A: While not yet tested in this context, digital PCR could theoretically support mixture interpretation for targeted SNP assays. However, it is not currently used for routine forensic genotyping.
Q: Are there specific sample types where digital PCR offers a clear advantage?
A: Digital PCR offers advantages for degraded, inhibited or low-template samples including bones, hair, touch DNA and environmental samples. Improved reproducibility and resistance to inhibitors are key benefits.
Q: Is there a commercially available mitochondrial DNA quantification assay for QIAcuity?
A: No commercial assay is currently available. Collaborative efforts are underway to translate validated research assays into broader solutions.
Looking ahead
Digital PCR is not a replacement for every forensic technique, but it is rapidly proving its value where accuracy, sensitivity and reproducibility matter most. From mitochondrial DNA quantification to emerging RNA-based body fluid identification, dPCR supports more confident decisions earlier in the forensic workflow. As validation continues and assays mature, dPCR is poised to become a part of modern forensic DNA analysis.
Listen to the discussion in more detail by watching the full on-demand webinar featuring researchers from King’s College London. See how dPCR can be applied to forensic casework and where it can add value in your own laboratory.